An Open-label, Multicenter, Phase 2 Trial Investigating the Efficacy and Safety of Daratumumab in Subjects with Multiple Myeloma Who Have Received at Least 3 Prior Lines of Therapy (Including a Proteasome Inhibitor and IMiD) or are Double Refractory to a Proteasome Inhibitor and an IMiD
ID Number 14-0092Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
Genetic research can help scientists understand how drugs work and what causes diseases. Janssen Research & Development LLC (the sponsor) would like to collect an extra blood sample from you to do genetic research. You are being asked for your permission for the Mount Sinai Multiple Myeloma Research Team to collect this sample from you for the purpose described in this form.
This optional research is not for your medical care. The research may help scientists to understand why HuMax-CD38 might work in some people, but not in others. It may also help explain why some people get multiple myeloma, but others do not. This information will be used to develop safer and better drugs.
Recruiting Patients: No